TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of tailored antithrombotic therapy with early
(<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid
maintenance] and aspirin) and late (>6-month post-PCI) deescalated (clopidogrel alone)
strategy in patients undergoing high-risk complex PCI as compared with standard Dual
Antiplatelet Therapy(aspirin and clopidogrel for 12 months).